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Changing Prescribing Patterns 
and Increasing Prescription Expenditures 
in Medicaid
ABSTRACT
PURPOSE Prescription drug expenditures are the most rapidly growing component 
of total health care expenditures and particularly affect state Medicaid programs. We 
determined the extent to which increasing prescription price and changing prescrib-
ing patterns contribute to rising prescription expenditures in Medicaid.
METHODS We conducted a claims-based analysis comparing annual prescription 
drug expenditures and prescribing patterns. Prescription drug and outpatient 
visit claims for all North Carolina Medicaid enrollees from 1998 through 2000 
were included. We analyzed drugs individually by combining all prescriptions and 
expenditures for the same drug formulation, and we calculated the number of 
units dispensed per person-year of enrollment.
RESULTS Prescription drug coverage for 1 person-year cost $503 in 1998 and 
$759 in 2000, for an annual increase of 22.8%. The average number of pre-
scriptions fi lled per person-year increased from 13.0 in 1998 to 15.5 in 2000. 
Increased prescribing for 6 drugs accounted for more than 25% of the total 
increase in expenditures. The price for the 15 most expensive drugs increased an 
average of 4.1% annually. 
CONCLUSIONS Prices for existing drugs increased slightly during the study period, 
but the major cause of the increase in drug costs was an increase in the number 
of prescriptions for new and more expensive medications. Prescribing patterns 
in Medicaid differ somewhat from those in the private sector and partly refl ect 
the population with low socioeconomic status and high health care needs that 
it serves. To help control rising prescription drug expenditures, efforts should be 
undertaken to improve appropriate and cost-effective prescribing.
Ann Fam Med 2004;2:488-493. DOI: 10.1370/afm.121.
INTRODUCTION 
Prescription drug expenditures are the most rapidly growing compo-nent of total health care expenditures, and the widespread growth in prescription expenditures has particularly affected state Medicaid 
programs. In 2000, the annual rate of growth of prescription expenditures 
was 21.4% in Medicaid compared with 17.3% nationally.1 Medicaid costs 
now comprise one of the largest items in state budgets and continue to 
grow.2 States are struggling to fi nd ways to control these costs.
Two main factors contributing to rising prescription drug expenditures 
are price and use.3,4 Because the majority of state Medicaid programs have 
unrestricted formularies, clinicians have greater freedom with their prescrib-
ing patterns; therefore, use in Medicaid may be different than in the private 
sector. Changes in prescribing patterns have been shown to result in increased 
expenditures in the private sector,3,5 but such studies in Medicaid are lacking.6
Because Medicaid covers a population with low socioeconomic status 
and high health care needs, in most cases has unrestricted formularies, and 
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is being disproportionately affected with increasing 
prescription drug expenditures, we conducted a 3-year 
claims-based analysis of one state’s Medicaid program 
to determine the extent to which increasing price and 
changing prescribing patterns contribute to rising pre-
scription expenditures.
METHODS
Data for the period of July 1, 1997, through June 30, 
2000, were obtained from the North Carolina Depart-
ment of Health and Human Services Division of 
Medical Assistance, Section of Medicaid Management 
Information Systems, which contracts with Electronic 
Data Systems Corporation (EDS) to process all claims, 
including prescription drug and outpatient visit claims 
for Medicaid enrollees. Monthly Medicaid enrollment 
data were used to calculate person-years of enrollment 
for the study period, a method that converts the total 
and often volatile person-months of enrollment into 
an equivalent number of people enrolled for an entire 
year. Thus, we did not account for new or continuous 
enrollment, and the only major change in coverage and 
eligibility was the addition of 73,000 people dually 
enrolled in Medicaid and Medicare during the study 
period. We analyzed outpatient visit rates and com-
plexities as a proxy for disease burden using Current 
Procedural Terminology evaluation and management 
codes. Reimbursed claims for prescriptions included 
the $5.60 pharmacist dispensing fee and excluded the 
$1.00 recipient copayment, both of which were in 
effect for the entire study period. We were unable to 
differentiate new prescriptions from refi lls. Only 0.4% 
of claims were incomplete.
To determine drug prices, we analyzed drugs indi-
vidually by combining all prescriptions for the same 
drug formulation based on the dose for each unit. The 
unit price for each drug formulation was calculated by 
dividing the total expenditures for the drug formulation 
by the total number of units dispensed. The average 
price for all drugs was the mean of all the unit prices 
calculated both with and without weighting for volume 
dispensed, thus accounting for the infl uence of infre-
quently prescribed, extremely expensive drugs and 
refl ecting the perceived price increase. Because claims 
data do not provide dosing of insulin, it was excluded 
from the drug-specifi c analyses. To determine prescrib-
ing rates and describe patterns, we used the number of 
units dispensed per person-year of enrollment. 
RESULTS
In 1998, 1,204,728 people were enrolled in the 
North Carolina Medicaid program for an average of 
9.1 months, or 0.76 years. The characteristics of the 
enrollees for each year are shown in Table 1 and were 
similar among the years. Enrollees made an average of 
2 visits per year to a physician, and the visit rates and 
complexities were similar for all 3 years. Prescription 
expenditures increased substantially during the study 
period. The amount spent on prescription drugs totaled 
$461 million in 1998 and increased to $748 million 
in 2000 (Table 1). Prescription coverage for 1 person-
year in North Carolina Medicaid cost $503 in 1998 
and $759 in 2000, an annual increase of 22.8%. The 
average number of prescriptions fi lled per person-year 
increased from 13.0 in 1998 to 15.5 in 2000. The unit 
price remained stable for medications available for all 
3 years but increased dramatically for the newly intro-
duced ones (Figure 1).
Changing prescribing patterns was the main con-
tributor to the rise in prescription expenditures. The 15 
drugs with the greatest expenditures in 2000 are listed 
in Table 2. These expenditures refl ect both the price of 
the drug and the frequency with which it is prescribed. 
Topping the list is omeprazole (Prilosec), for which 
$36.2 million was spent in 2000, up by $15.9 million 
(79%) from 1998. This $15.9 million increase in Prilo-
sec spending was 5.5% of the $287 million increase in 
total prescription expenditures from 1998 to 2000. Six 
drugs accounted for more than 25% of the increase in 
prescription expenditures. 
The price for the 15 most expensive drugs increased 
by an average of 4.1% annually, while the consumer 
price index increased by approximately 3.9% annually.7 
The increase in expenditures for these drugs therefore 
resulted mainly from a marked increase in their fre-
quency of being prescribed (Table 2). For example, in 
1998, 6.0 million tablets of Prilosec were dispensed 
(6.5 per person-year), which increased to 9.8 million 
dispensed tablets (9.9 per person-year) in 2000, and 
celecoxib (Celebrex) was not available in 1998, but 6.9 
million tablets (7.0 per person-year) were dispensed to 
Medicaid enrollees in 2000.
DISCUSSION
Changing prescribing patterns is the factor most 
responsible for rising prescription expenditures in this 
population. Our fi ndings show that individual drug 
prices did not increase markedly, but that prescribing 
patterns dramatically shifted to favor existing and new 
higher cost medications from 1998-2000 in the North 
Carolina Medicaid program. The North Carolina Med-
icaid program ranked 37th among states in prescription 
expenditures per enrollee in 1997.8 
Some of the factors contributing to increased pre-
scription expenditures in Medicaid are similar to the 
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factors described nationwide. The National Institute 
for Health Care Management3 analyzed prescription 
data from retail pharmacy outlets, fi nding that a few 
drugs were largely responsible for the increases in 
prescription expenditures and that the increase in the 
average cost per prescription was largely affected by 
shifting prescribing patterns to more expensive drugs. 
Dubois and colleagues4 analyzed managed care and fee 
for service claims-based data sets, fi nding that volume 
factors accounted for the vast majority of the increases 
in expenditures. Shifting prescribing patterns and 
increasing volume to favor existing and new higher 
cost medications result from changes in physicians’ 
care. An example for increased use of existing drugs 
is proton pump inhibitors (PPIs) and of new drugs is 
cyclooxygenase-2 (COX-2) inhibitors. From 1998 to 
2000, the number of prescriptions for the PPIs Prilosec 
and lansoprazole (Prevacid) increased 97% nationwide; 
celecoxib (Celebrex) and rofecoxib (Vioxx) became 
available in 1999, but more than $20 million was spent 
on them in 2000. Some patients receive additional 
benefi t from being on such drugs rather than thera-
peutic substitutes, but what level of benefi t warrants 
being treated with a more expensive medication, such 
as a PPI or COX-2 inhibitor, is not always clear, may be 
diffi cult to assess clinically, and is often lacking estab-
lished recommendations. 
Some of the drugs with the greatest expenditures 
in the North Carolina Medicaid program are similar to 
those nationally. Along with 4 aforementioned drugs—
Prilosec, Prevacid, Celebrex, and Vioxx— loratadine 
(Claritin), fl uoxetine (Prozac), paroxetine (Paxil), 
sertraline (Zoloft), amlodipine (Norvasc), atorvastatin 
(Lipitor), and metformin (Glucophage) all appear on 
the national top 20 drug lists for dispensed prescrip-
tions and dollar sales.5 Some drugs are prescribed 
more frequently in Medicaid, however. Of note, our 
list includes the atypical antipsychotics olanzapine 
(Zyprexa) and risperidone (Risperdal) and the antiepi-
leptic gabapentin (Neurontin). Although 3 of these 4 
Table 1. Description of Enrollees, Visits, and Prescriptions in the North Carolina Medicaid Program, 
1998-2000
Characteristics 1998 1999 2000
Enrollees
No. 1,204,728 1,228,641 1,232,271
Age, mean (SD), years 29 (28) 28 (28) 27 (27)
Female, % 61 60 60
Race, %
Black 50 48 46
Hispanic 2 3 4
White 38 40 42
Other 10 9 8
Average length of enrollment, years 0.76 0.76 0.80 
Total person-years 915,873 931,810 986,260
Visits
No. 1,959,412 1,968,187 1,866,831
Type, %
New 7.4 6.6 6.1
Follow-up 88.5 89.5 89.8
Consultation 4.1 3.9 4.1
Complexity, %
Minimally 3.8 3.4 3.2
Somewhat 20.5 19.7 17.8
Moderately 58.9 60.1 61.2
Highly 13.8 13.8 14.8
Extremely 3.1 2.9 3.0
Average No. of visits per person-year 2.1 2.1 1.9
Prescriptions
No. 11,895,277 13,247,904 15,261,907
Expenditures, $ 460,748,584 575,379,831 748,432,849
Average prescription cost, $ 39 43 49
Average No. of prescriptions per person-year 13.0 14.2 15.5
Cost of prescription coverage per person-year, $ 503 617 759
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drugs appear on the national top 20 drug list for dollar 
sales, none appears on the top 20 drug list for prescrip-
tions dispensed. This disparity refl ects the very high 
cost of these drugs and the dissimilarity between Med-
icaid populations and national samples. 
In Medicaid, prescription drug expenditures are 
disproportionately spent for certain groups. Approxi-
mately 80% of Medicaid drug expenditures nation-
ally are spent for the blind, disabled, or elderly, even 
though these groups make up 26% of Medicaid enroll-
ees.5,9 In North Carolina in 1999, persons who were 
blind, disabled, or elderly made up 33% of Medicaid 
enrollees and were responsible for 83% of prescription 
drug expenditures. Although our fi ndings may be gen-
eralizable to other Medicaid programs that have unre-
stricted formularies, they may not be generalizable to 
programs with restricted formularies or those serving 
non-Medicaid populations. Our study is limited in that 
we did not adjust the rates of prescribing for disease 
prevalence and severity, and using visit rates and com-
plexities as proxies has limitations. Because substantial 
fl ux exists among those who are enrolled in Medicaid 
throughout a year, prescribing may be increased for 
those with new prescription drug coverage. Although 
this phenomenon may contribute to the fi ndings, the 
infl uence would be modest on each year based on the 
low rates of new visits and average lengths of enroll-
ment exceeding 9 months per year, and it would not 
explain differences among the years based on the sta-
bility of these measures. In addition, our calculation 
of costs for Medicaid did not take into account manu-
facturer rebates or discounts, and we did not evaluate 
inpatient use. 
Although the results of our study can serve as a 
benchmark top 20 for other Medicaid programs, their 
major contribution is to generate hypotheses about 
the quality of prescribing and care for this population. 
What is prescribed is ultimately at the discretion of the 
clinician, who has to consider carefully the cost-benefi t 
ratio of the possible treatments for every patient. Phy-
sicians might believe that the newer, more expensive 
drugs offer advantages over older, less expensive drugs, 
such as more convenient dosing, fewer adverse effects, 
and improved effi cacy. Therapy with these newer 
drugs can reduce rates of symptoms, outpatient visits, 
and complications requiring hospitalizations; however, 
for most of these drugs, improved cost-effectiveness 
has not been shown.10 The rise in prescription expendi-
* Unweighted = ( unit price for each drug)/(number of drugs).
† Weighted = ( units dispensed for each drug)/( expenditures for each drug).
Figure 1. Average unit price for existing and new drugs, unweighted (top) and weighted (bottom) 
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tures needs to be compared with other health care sav-
ings. Increased prescribing in some cases is desirable, 
such as the use of -blockers and warfarin by patients 
who have a history of myocardial infarction and atrial 
fi brillation, respectively. Some prescribing patterns, 
however, are neither cost-effective nor evidence based.
Many clinicians prescribe certain medications 
with the goal of providing high-quality care; however, 
clinicians may be uninformed or misinformed. For 
example, amlodipine (Norvasc) is being prescribed at 
a frequency comparable to that of other antihyperten-
sive medications, which suggests that Norvasc is often 
being used as a fi rst-line agent; however, evidence does 
not support using calcium channel blockers in this 
manner.11 A putative reason for the widespread use of 
Norvasc is pharmaceutical marketing. Direct-to-con-
sumer advertising and physician detailing have been 
shown to affect prescribing patterns.12 Some of the 
drugs with the greatest expenditures in this study, par-
ticularly those that were new and expensive, are among 
those with the largest marketing budgets.5 Vioxx, Pri-
losec, Claritin, Paxil, and simvastatin (Zocor) were the 
5 drugs with the greatest spending on direct-to-con-
sumer advertising in 2000 in the United States. A total 
of $551 million was spent on direct-to-consumer adver-
tising and was associated with an 87% average increase 
in sales rates, corresponding to a total increase in sales 
for the 5 drugs of $2.7 billion.13 Direct-to-consumer 
advertising represented 16% of promotional spending, 
with hospital detailing, physician’s offi ce detailing, and 
samples accounting for 5%, 26%, and 50%, respec-
tively.13 Pharmaceutical marketing affects not only 
physicians and patients but also the physician-patient 
relationship.14 Physicians are infl uenced by marketing, 
and they may be more likely to prescribe those prod-
ucts in unrestricted formularies, such as formularies in 
Medicaid programs.
There is an important role for many of the newer and 
more expensive medications, but that role must be bet-
ter defi ned and followed. One challenge for physicians 
is balancing caring for individuals and for populations. 
This study is one of a population, but physicians mostly 
care for populations one individual at a time. Additional 
research is needed on the cost-effectiveness of medica-
tions, but in the meantime, clinicians can make more of an 
effort to prescribe appropriately and judiciously.
To read or post commentaries in response to this article, see it 
online at http://www.annfammed.org/cgi/content/full/2/5/488. 
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Table 2. Expenditures and Frequency of Prescribing for the 15 Most Expensive Drugs 


























Omeprazole Prilosec 36.2 15.9 5.5 5.5 6.5 8.4 9.9
Olanzapine Zyprexa 28.4 15.4 5.3 10.8 2.4 3.8 4.6
Risperidone Risperdal 20.8 8.8 3.0 13.9 4.6 5.4 6.6
Lansoprazole Prevacid 20.4 14.8 5.1 19.0 1.9 3.6 5.9
Celecoxib Celebrex 13.0 13.0 4.5 23.6 0.0 1.9 7.0
Loratadine Claritin 12.4 6.0 2.1 25.6 3.5 4.8 5.8
Fluoxetine Prozac 11.3 3.2 1.1 26.8 3.8 4.2 4.6
Valproic acid Depakote 10.6 4.2 1.5 28.2 4.5 5.5 6.7
Amlodipine Norvasc 10.6 4.4 1.5 29.7 8.5 10.0 10.9
Paroxetine Paxil 10.1 3.7 1.3 31.0 3.5 4.1 4.5
Sertraline Zoloft 10.1 3.2 1.1 32.2 3.6 4.2 4.7
Ranitidine Zantac 9.8 –3.6 –1.3 30.9 1.4 2.8 4.4
Atorvastatin Lipitor 9.7 7.1 2.5 33.4 9.5 8.5 8.2
Gabapentin Neurontin 9.1 5.8 2.0 35.4 3.8 5.9 9.1
Metformin Glucophage 7.5 4.6 1.6 38.0 5.6 7.8 10.4
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